Razpipadon

Razpipadon
Clinical data
Other namesCVL-871; CVL871; PF-06669571; PF06669571; PF-6669571; PF6669571; PW-0464; PW0464
Routes of
administration
Oral
Drug classDopamine receptor agonist; Dopamine D1 and D5 receptor agonist
Identifiers
  • (−)-(6P)-6-(4-{[3-(difluoromethoxy)pyridin-2-yl]oxy}-2-methylphenyl)-1,5-dimethylpyrimidine-2,4(1H,3H)-dione
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC19H17F2N3O4
Molar mass389.359 g·mol−1
3D model (JSmol)
  • CC1=C(C=CC(=C1)OC2=C(C=CC=N2)OC(F)F)C3=C(C(=O)NC(=O)N3C)C
  • InChI=1S/C19H17F2N3O4/c1-10-9-12(27-17-14(28-18(20)21)5-4-8-22-17)6-7-13(10)15-11(2)16(25)23-19(26)24(15)3/h4-9,18H,1-3H3,(H,23,25,26)
  • Key:ZXIPVZWZRQCIRW-UHFFFAOYSA-N

Razpipadon (developmental codes CVL-871, PF-06669571, and PW-0464) is a dopamine receptor agonist which is under development for the treatment of dementia-related apathy. It is taken orally.

Razpipadon acts as a selective partial agonist of the dopamine D1 and D5 receptors.

The drug was originated by Pfizer and is under development by Cerevel Therapeutics. As of April 2022, razpipadon is in phase 2 clinical trials for dementia-related apathy. It was also previously under development for Parkinson's disease and cognition disorders, but development for these indications was discontinued.

See also